Sirolimus Gel for Angiokeratoma Treatment
Part of Cancer clinical trials.
This trial tests a topical gel (a cream you apply to skin) containing sirolimus to treat angiokeratomas, which are small growths on the skin. The goal is to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 years old
- You have been diagnosed with angiokeratoma (small vascular skin growths)
- You can commit to following all study visits, tests, and instructions
- You are willing to apply the study gel as directed and attend follow-up appointments
- You have no serious allergies or reactions to sirolimus or similar medications
- You don't have other serious health conditions that would make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
This pilot study tests a gel called sirolimus to see if it can safely shrink or improve raised, dark birthmarks (epidermal nevi) in people 6 and older. The gel is applied directly to the birthmark, and the study will check how well it works and if it causes any side effects.
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
This Phase 3 study tests the safety and how the body absorbs (pharmacokinetics) of a rapamycin gel called QTORIN 3.9% in adults with pachyonychia congenita. It may help determine whether this gel is safe and works for people with this rare skin nail condition.
This trial tests a new topical gel (TOR-582) applied inside the nose to reduce nosebleeds in people with HHT. It may help by targeting the abnormal blood vessels that cause frequent bleeding.
Hear when a new Angiokeratomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.